Guidelines
Community Acquired Pneumonia

Community Acquired Pneumonia

Guideline Use

Dose recommendations are based on patients with normal renal function. Refer to dosing in renal impairment

These guidelines may not be appropriate for patients with a history of multi-drug resistant organisms. Consider infectious disease consultation

Diagnostics

Management Considerations

Patients hospitalized with suspected or confirmed Influenza A can be started on oseltamivir regardless of time from symptom onset5

Deescalation

Additional Information

Last Updated: August, 2021

These recommendations are meant to guide empiric therapeutic decision making and are not meant to replace sound clinical decision making. Definitive therapy should be based on culture and susceptibility reports

  • Kyle D. Massey, PharmD, BCIDP
  • Rebekah Gass, MD
  • Kelly M. Sawyer, PharmD, BCIDP
  1. Metlay, J. P., Waterer, G. W., Long, et al. Diagnosis and treatment of adults with community-acquired pneumonia. American Journal of Respiratory and Critical Care Medicine, 200(7), E45–E67. Available here
  2. El-sohl A, Pietrantoni C, Bhat A, et al. Microbiology of severe aspiration pneumonia in institutionalized elderly. American Journal of Respiratory and Critical Care Medicine. 2003;167:1650-1654. Available here
  3. Longo D. Aspiration pneumonia. NEJM. 2019;380:651-663. Available here
  4. Gross A, Schooneveld T, Olsen K, et al. Epidemiology and predictors of multidrug-resistant community-acquired and health care-associated pneumonia. AAC. 2014;58:5262-5268. Available here
  5. Katzen J, Kohn R, Houk J. Early oseltamivir after hospital admission is associated with shortened hospitalization: a 5-Year analysis of oseltamivir timing and clinical outcomes. CID. 2019;69:52-58. Available here